Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45. Individuals over the age of 45 will not be included as we are examining the effects of menstrual cycle and ovarian hormones.~* Daily smokers who smoke at least 10 cigarettes per day for at least past 6 months.~* Post menarche and pre menopausal~* Regular menstrual cycle between 25 and 35 days~* At least three months post delivery and breast feeding~* Desire to quit smoking and willingness to participate in a research study.~* Women with a history of depression (but not current MDE) and current PMDD will be included. Excluding women with these diagnoses would have a major impact on feasibility, but because both disorders might impact treatment outcome, individuals will be stratified across randomization groups.~Exclusion Criteria:~* Any unstable major axis I psychiatric disorder in the past month~* Current substance use disorders other than nicotine and caffeine use, in the past 30 days.~* Any medication that may interfere with psychophysiological monitoring~* Unstable medical or serious medical condition in the past 6 months~* Hypersensitivity to varenicline or TNP~* Use of other tobacco products~* Use of other medications with smoking cessation efficacy within 30 days prior to enrollment~* BMI less than 15 since this could alter hormone levels that affect menstrual phase~* Pregnancy~* Breast feeding~* Status post hysterectomy~* Birth control or HRT medication that would effect the menstrual cycle. Currently available oral contraceptives contain either a combination of a synthetic estrogen and synthetic progestin, or a progestin alone. Estrogen and/or progestin inhibit ovulation and alter cervical mucus and the endometrium by suppressing the production of follicle-stimulating hormone and the luteinizing hormone surge (Bucci \& Carson, 1997)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
- Transdermal Nicotine Patch (Type: ACTIVE_COMPARATOR): Participant randomized to receive active transdermal nicotine patch and placebo varenicline.

Based on this trial design, predict the completion outcome and termination type (if applicable).